Food and Drug Administration (FDA) said that progesterone shots should no longer be used to prevent preterm birth
Vaginal progesterone and 17-OHPC both reduced birth before 34 weeks' gestation in high-risk singleton pregnancies
Results: Midwifery-led care was underutilized by groups most at risk for preterm birth and was shown to be effective at maintaining low preterm birth rates
Access ACOG’s Practice Advisory “ Updated Clinical Guidance for the Use of Progesterone Supplementation for the Prevention of Recurrent Preterm Birth
The primary outcome, incidence of respiratory distress syndrome, was similar in both groups: 10
Since PTB is a major cause of worldwide neonatal mortality and morbidity, its prevention is of high priority in obstetric care
Background: Preterm birth is a major complication of pregnancy associated with perinatal mortality and morbidity
Another standard method to prevent preterm birth is the use of progesterone supplementation
1 However, because of issues that are related to access and side-effects, adherence to 17OHPC is not always ideal 2,3 and may impact its effectiveness adversely in the real world
“ACOG recognizes that the PROLONG clinical trial evaluating 17p in patients with a history of a prior spontaneous singleton preterm Introduction to management and issues of preterm birth